PMID- 27277337 OWN - NLM STAT- MEDLINE DCOM- 20170406 LR - 20181202 IS - 1791-3004 (Electronic) IS - 1791-2997 (Linking) VI - 14 IP - 2 DP - 2016 Aug TI - Autophagic death induced by thermo‑chemotherapy in gastric cancer cells results from the reactive oxygen species pathway. PG - 1210-8 LID - 10.3892/mmr.2016.5353 [doi] AB - Gastric cancer is the third leading type of cancer and has the third leading cancer‑associated mortality in China. The mechanism of thermo‑chemotherapy in gastric cancer cells remains to be elucidated. The present study aimed to investigate the role of autophagic cell death in the thermo‑chemotherapy of gastric cancer. The current study included four groups: An empty control group, a hyperthermia group, a chemotherapy (oxaliplatin) group, and a thermo‑chemotherapy group. Cell viability was analyzed by the MTS assay. Production of intracellular reactive oxygen species (ROS) was quantified by flow cytometry. Autophagy‑associated proteins, Beclin 1, microtubule‑associated protein 1A/1B‑light chain (LC3B) and mammalian target of rapamycin (mTOR), were determined by western blot analysis. The results indicated that thermo‑chemotherapy markedly increased intracellular ROS production, and decreased mitochondrial membrane potential. The transmission electron microscopy results indicated that thermo‑chemotherapy induced production of autophagic bodies. In addition, thermo‑chemotherapy‑induced cell damage at the cellular and animal levels indicated a notable increase in the expression of the autophagy‑associated genes, LC3B and Beclin 1. A negative correlation between mTOR expression and autophagy was also identified, which demonstrates that thermo‑chemotherapy induces autophagic cell death by activating the autophagy‑associated signaling pathways. The results of the present study demonstrated that the ROS level is important in autophagic death of the gastric carcinoma cells, and the increased ROS level, induced by thermo‑chemotherapy treatment, induced autophagy in gastric carcinoma cells. FAU - Wu, Yinbing AU - Wu Y AD - Treatment Center of Body Cavitary Thermo‑perfusion, Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China. FAU - Pan, Mingxin AU - Pan M AD - Second Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, P.R. China. FAU - Cui, Shuzhong AU - Cui S AD - Treatment Center of Body Cavitary Thermo‑perfusion, Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China. FAU - Ba, Mingchen AU - Ba M AD - Treatment Center of Body Cavitary Thermo‑perfusion, Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China. FAU - Chen, Zulong AU - Chen Z AD - Treatment Center of Body Cavitary Thermo‑perfusion, Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China. FAU - Ruan, Qiang AU - Ruan Q AD - Treatment Center of Body Cavitary Thermo‑perfusion, Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China. LA - eng PT - Journal Article DEP - 20160527 PL - Greece TA - Mol Med Rep JT - Molecular medicine reports JID - 101475259 RN - 0 (Antineoplastic Agents) RN - 0 (Apoptosis Regulatory Proteins) RN - 0 (Biomarkers) RN - 0 (Organoplatinum Compounds) RN - 0 (Reactive Oxygen Species) RN - 04ZR38536J (Oxaliplatin) SB - IM MH - Animals MH - Antineoplastic Agents/*pharmacology MH - Apoptosis Regulatory Proteins/genetics/metabolism MH - Autophagy/*drug effects/*radiation effects MH - Biomarkers MH - Cell Line, Tumor MH - Cell Survival/drug effects/radiation effects MH - Disease Models, Animal MH - Drug Resistance, Neoplasm MH - *Hot Temperature MH - Humans MH - *Hyperthermia, Induced MH - Inhibitory Concentration 50 MH - Membrane Potential, Mitochondrial/drug effects/radiation effects MH - Mice MH - Organoplatinum Compounds/pharmacology MH - Oxaliplatin MH - Reactive Oxygen Species/*metabolism MH - Signal Transduction/*drug effects/*radiation effects MH - Stomach Neoplasms/drug therapy/genetics/*metabolism/pathology MH - Xenograft Model Antitumor Assays EDAT- 2016/06/10 06:00 MHDA- 2017/04/07 06:00 CRDT- 2016/06/10 06:00 PHST- 2015/05/13 00:00 [received] PHST- 2016/02/25 00:00 [accepted] PHST- 2016/06/10 06:00 [entrez] PHST- 2016/06/10 06:00 [pubmed] PHST- 2017/04/07 06:00 [medline] AID - 10.3892/mmr.2016.5353 [doi] PST - ppublish SO - Mol Med Rep. 2016 Aug;14(2):1210-8. doi: 10.3892/mmr.2016.5353. Epub 2016 May 27.